Evidence map›Paper›PMID 26211987›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Robert Chen, Joycelynne M Palmer, Peter Martin, Nicole Tsai, Young Kim, Bihong T Chen, Leslie Popplewell, Tanya Siddiqi, Sandra H Thomas, Michelle Mott and 5 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2018
    Trial
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. When should we use it? The role of brentuximab vedotin in 2024.Hematology. American Society of Hematology. Education Program · 2024
    Review
  17. When to use stem cell transplantation for classical Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2024
    Review
  18. Article
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Robert ChenDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California. Electronic address: rwc755@gmail.com.
Joycelynne M PalmerDepartment of Information Sciences, Division of Biostatistics, City of Hope, Duarte, California.
Peter MartinDepartment of Hematology/Oncology, Weill Cornell Medical College, New York, New York.
Nicole TsaiDepartment of Information Sciences, Division of Biostatistics, City of Hope, Duarte, California.
Young KimDepartment Pathology, City of Hope, Duarte, California.
Bihong T ChenDepartment Diagnostic Radiology, City of Hope, Duarte, California.
Leslie PopplewellDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Tanya SiddiqiDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Sandra H ThomasDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Michelle MottDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Firoozeh SahebiDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope, and Kaiser Permanente, Los Angeles, California.
Saro ArmenianDepartment of Population Sciences, City of Hope, Duarte, California.
John LeonardDepartment of Hematology/Oncology, Weill Cornell Medical College, New York, New York.
Auayporn NademaneeDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Stephen J FormanDepartment of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
City of Hope · USCornell University · USKaiser Permanente · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5M
Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
NCI NIH HHS K12 CA001727NCI NIH HHS K12CA001727NCI NIH HHS P30 CA033572NCI NIH HHS P30CA33572NCI NIH HHS P50 CA107399
6 · The paper itself

Abstract

This multicenter prospective phase II study examines the activity and tolerability of brentuximab vedotin as second-line therapy in patients with Hodgkin lymphoma that was relapsed or refractory after induction therapy. Brentuximab vedotin (1.8 mg/kg) was administered i.v. on day 1 of a 21-day cycle for a total of 4 cycles. Patients then proceeded to autologous hematopoietic cell transplantation (AHCT), if eligible, with or without additional salvage therapy, based on remission status after brentuximab vedotin. The primary endpoint was overall response rate (ORR). Secondary endpoints were safety, stem cell mobilization/collection, AHCT outcomes, and association of CD68(+) with outcomes. Of 37 patients, the ORR was 68% (13 complete remission, 12 partial remission). The regimen was well tolerated with few grade 3/4 adverse events, including lymphopenia (1), neutropenia (3), rash (2), and hyperuricemia (1). Thirty-two patients (86%) were able to proceed to AHCT, with 24 patients (65%) in complete remission at time of AHCT. Thirteen patients in complete remission, 4 in partial remission, and 1 with stable disease (49%) received AHCT without salvage combination chemotherapy. CD68 expression did not correlate with response to brentuximab vedotin. The median number of stem cells mobilized was 6.0 × 10(6) (range, 2.6 to 34), and median number of days to obtain minimum collection (2 × 10(6)) was 2 (range, 1 to 6). Brentuximab vedotin as second-line therapy is active, well tolerated, and allows adequate stem cell collection and engraftment. For Hodgkin lymphoma patients with relapsed/refractory disease after induction therapy, second-line brentuximab vedotin, followed by combination chemotherapy for residual disease, can effectively bridge patients to AHCT.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinChildDrug Administration ScheduleFemaleHematopoietic Stem Cell MobilizationHodgkin DiseaseHumansHyperuricemiaImmunoconjugatesLymphopeniaBrentuximab VedotinImmunoconjugatesAutologous hematopoietic transplantationBrentuximab vedotinHodgkin lymphomaSalvage

Identifiers

PMID26211987
PMCPMC4639410
OpenAlexW950004053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.